CALC · CalciMedica, Inc. · Investor Relations

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and

CalciMedica’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 31, 2026 LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated

Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND submission both anticipated in mid-2027 FDA aligned that the primary endpoint for the

FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a strategy to evaluate elevated lactate dehydrogenase (LDH) as a potential enrichment marker for

Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H

FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue clinical development of Auxora across indications LA JOLLA, Calif., June 24, 2026 /PRNewswire/ --

FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected

Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026 JCI Insight publication of preclinical

Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora ™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreatitis (AP); final trial design expected in 1H 2026 Cash position expected to fund operations into 2H

Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with existing treatments Cardiac benefit supports the mechanistic rationale for CRAC channel

Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of AKI Findings reinforce the mechanistic rationale for Auxora as a potential treatment for severe AKI

AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials LA JOLLA, Calif. , Oct. 14, 2025 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage

LA JOLLA, Calif. , Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and